# Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer

> **NCT05913570** · PHASE2 · UNKNOWN · sponsor: **LiuYing** · enrollment: 22 (estimated)

## Conditions studied

- Colorectal Cancer
- Mismatch Repair-deficient (dMMR)
- Microsatellite Instability-high (MSI-H)
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody

## Key facts

- **NCT ID:** NCT05913570
- **Lead sponsor:** LiuYing
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-20
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913570, "Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05913570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*